Emotional Processing for Traumatic Brain Injury (TBI)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Traumatic Brain Injury (TBI)+5 More
Emotional Processing - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial suggests that an emotional processing program, modified for children, is an effective treatment for those with a TBI.

Eligible Conditions
  • Traumatic Brain Injury (TBI)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 8 weeks

8 weeks
Facial Identification Task

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Emotional Processing
1 of 2
Control intervention
1 of 2

Experimental Treatment

Non-Treatment Group

45 Total Participants · 2 Treatment Groups

Primary Treatment: Emotional Processing · Has Placebo Group · N/A

Emotional Processing
Behavioral
Experimental Group · 1 Intervention: Emotional Processing · Intervention Types: Behavioral
Control intervention
Behavioral
PlaceboComparator Group · 1 Intervention: Emotional Processing · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks

Who is running the clinical trial?

Kessler FoundationLead Sponsor
153 Previous Clinical Trials
10,254 Total Patients Enrolled
28 Trials studying Traumatic Brain Injury (TBI)
1,817 Patients Enrolled for Traumatic Brain Injury (TBI)

Eligibility Criteria

Age < 18 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The text states that a person must have a sustained a TBI at least 1 year ago in order to participate in the study
The children are aged nine and seventeen and they are able to speak and read English fluently.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: November 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.